Hematology & Oncology
University Pediatricians | Michigan
About the Division of Pediatric Hematology / Oncology
The Division of Pediatric Hematology/Oncology consists of 18 physician faculty members, 6 fellows, 9 nurse practitioners, 22 registered nurses, 4 social workers, 3 hematology/oncology pharmacist specialists, 1.5 psychologist, 5 research assistants in the diagnostic special coagulation and flow cytometry labs, and additional research support staff for clinical trials and division support staff.
The Division treats a wide range of pediatric, adolescent and young adult patients with both oncologic and hematologic disorders. This includes over 125 new oncology patients, performs approximately 20 stem cell transplants each year and over 1,000 cancer survivors receive ongoing follow-up care. Over 400 patients with a wide range of bleeding disorders including hemophilia, von Willebrand disorder, platelet dysfunction and thrombosis are actively followed. The comprehensive Sickle Cell Center has over 700 patients receiving active care from birth through young adulthood.
The Division has over 10,000 outpatient visits per year at the main hospital (Children’s Hospital of Michigan-Midtown Detroit) in our outpatient clinic consisting of 13 exam rooms, 14 infusion rooms, a dedicated operating room/procedure room and an inpatient Hematology/Oncology and Stem Cell unit with 32 beds. Outpatient care including chemotherapy/transfusion/infusions are also provided at our suburban satellite ambulatory site at Children’s Hospital of Michigan-Troy.
Division Leadership
My Philosophy of Care
“Having walked in the shoes of a patient at the very same hospital where I now practice, I understand firsthand the anxiety, fear, and uncertainty that families face. My goal is to combine cutting-edge science with deeply personal, empathetic care, treating every child not just as a medical case, but as a resilient individual who deserves a full, healthy future.”
Jeffrey W. Taub, MD
Division Chief, Pediatric Oncology
Ring Screw Textron Endowed Chair in Pediatric Cancer Research
About Dr. Taub
Dr. Jeffrey W. Taub is the Division Chief of Pediatric Oncology at the Children’s Hospital of Michigan and a Professor of Pediatrics at the Wayne State University School of Medicine. With more than 35 years of clinical and academic experience, Dr. Taub is widely recognized for his expertise in childhood blood cancers, pioneering clinical trials, and deeply personalized patient care.
Dr. Taub’s path to becoming a pediatric oncologist is uniquely personal. After surviving Hodgkin lymphoma as a teenager at the Children’s Hospital of Michigan in 1977, he dedicated his life to treating children facing the very same diagnoses. This experience fuels his compassionate, family-centered approach to care, ensuring every young patient and their loved ones feel supported, heard, and deeply cared for throughout their medical journey.
Areas of Expertise
- Childhood Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)
- Leukemia and Lymphoma in children with Down syndrome
- Retinoblastoma and general pediatric oncology
- Cancer survivorship and long-term follow-up care
Research & Innovations
In addition to his clinical work, Dr. Taub is a leading researcher dedicated to finding safer, more effective treatments for childhood cancers including helping to direct national clinical trials. He has published over 180 peer-reviewed scientific papers listed on Pubmed in leading medical journals including Blood, JAMA Oncology, Leukemia, Cancer Research, Clinical Cancer Research, Biochemical Pharmacology and Pediatric Blood & Cancer. His translational research projects have been supported by extramural funding for over the past 30 years from the National Institutes of Health/National Cancer Institute, Blood Cancer United (Leukemia & Lymphoma Society), the Children’s Oncology Group and the American Society of Clinical Oncology. His primary research focus includes:
- Down Syndrome and Leukemia: Developing tailored, safer chemotherapy protocols that dramatically improve survival rates for children with Down syndrome.
- Overcoming Chemotherapy Resistance: Investigating new ways to make standard treatments more effective against aggressive leukemia cells.
- Environmental Cancer Triggers: Leading innovative research utilizing zebrafish models to study how environmental factors might trigger human leukemia genes.
He has an H-index of 51 (2026), highlighting the high caliber of the research he has conducted and publications he has co-authored.
Education & Board Certifications
- Medical Degree: University of Western Ontario School of Medicine
- Residency: Pediatric Residency, Children’s Hospital of Michigan
- Fellowship: Pediatric Hematology/Oncology Fellowship, Children’s Hospital of Michigan
- Board Certifications: General Pediatrics, Pediatric Hematology/Oncology
Awards & Recognition
Dr. Taub is frequently honored for his clinical excellence and dedication to medicine. He is a multi-year recipient of the Castle Connolly “Top Doctor” designation, a recipient of the Physician Difference Maker Award, and was named a Health Care Hero by Crain’s Detroit Business. He is also an elected Fellow of the American Academy of Pediatrics.
Madhvi Rajpurkar, MD – Division Co-Chief
Bio coming soon…
Gene Therapy Zynteglo
Children’s Hospital of Michigan is revolutionizing beta thalassemia treatment with the groundbreaking gene therapy Zynteglo. This innovative approach involves adding a gene to the patient’s bone marrow stem cells, eliminating the need for lifelong interventions and mitigating side effects. Eligible patients can now undergo potentially curative treatment at the hospital, known for its expertise in stem cell transplantation and gene therapy. This milestone reflects the hospital’s commitment to exceptional care and fulfills the vision of its founder, Dr. Thomas Benton Cooley. Zynteglo offers hope and relief, particularly for patients of Mediterranean, South Asian, and Middle Eastern descent disproportionately affected by this genetic condition.
Evaluation & Diagnosis
Each child is evaluated by our team of specialists and an innovative, individualized customized treatment plan is formulated based on recommendations at our multidisciplinary pediatric tumor board, pediatric neuro-oncology tumor board or hematology board. This also includes the use of genomic analysis for diagnostic purposes and to identify targeted therapies when applicable.
The Division houses nationally recognized CAP certified clinical coagulation (Meera Chitlur: Medical Director) and clinical flow cytometry (Sureyya Savasan: Medical Director) laboratories which aid in the most up to date methods for diagnosing pediatric hematologic and oncologic disorders.
Multiple clinical trials for oncology, hemophilia, thrombotic disorders and sickle cell anemia are available for patients to receive the most up to date diagnostic and therapeutic treatments. The hospital is a member of the Children’s Oncology Group and is also a collaborating site for the St. Jude Children’s Research Hospital TOT17 acute lymphoblastic leukemia and AML16 acute myeloid leukemia clinical trials – protocols not available elsewhere in Michigan. Children are also eligible for enrollment in Head Start IV clinical trials for next consortium and the Blood and Marrow Transplant Clinical Trials Network clinical trials for stem cell transplants.
Our specialized clinical programs include
1. Total Therapy Study XVII (TOT17) For Newly Diagnosed Patients With Acute Lymphoblastic Leukemia And Lymphoma
2. AML16: A Phase II Trial Of Epigenetic Priming In Patients With Newly Diagnosed Acute Myeloid Leukemia
3. Patients under the age of 10 with either CNS embryonal tumors or medulloblastoma are eligible for enrollment on the HeadStart IV protocol which is a national collaborative study overseen by Nationwide Children’s Hospital: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
4. Treatment of Neuroblastoma and GD2-Postive Tumors with Activated T Cells Armed with OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study
CHM is a long-standing member of the Children’s Oncology Group (COG) which also enrolls patients on multiple trials for various pediatric cancers.
The Division of Hematology/Oncology’s Bone Marrow Transplant team at the Children’s Hospital of Michigan, in partnership with the Barbara Ann Karmanos Cancer Institute, provides expert care to children during allogeneic, haploidentical, autologous, peripheral stem cell and cord blood transplants. In 2007, the Children’s Hospital of Michigan opened the region’s only pediatric bone marrow transplant unit. The advanced unit includes private rooms equipped with cutting edge monitoring equipment and a HEPA filtration system to ensure the environment is highly protective against infection, a major complication for patients undergoing bone marrow transplants, and cutting-edge monitoring equipment.
A wide range of diagnoses have been treated and cured by transplants for both malignant and non-malignant disorders including: Acute lymphoblastic leukemia, Acute myeloid leukemia, Neuroblastoma; Hodgkin lymphoma; Non-Hodgkin lymphoma; Brain tumors (e.g. medulloblastoma); Rhabdomyosarcoma; Ewing sarcoma; Bone marrow failure disorders including aplastic anemia; Sickle cell anemia, beta thalassemia, immunodeficiencies, osteopetrosis, and Glanzmann’s thrombasthenia.
This multidisciplinary clinic provides ongoing follow up care to survivors of childhood/pediatric brain tumors to monitor for sequelae (late effects from their therapies). The medical team consists of pediatric oncologists, pediatric endocrinologists, pediatric neurologists, pediatric radiologists, pediatric neurosurgeons, pediatric radiation oncologists, nurses and social workers to ensure a high quality of life of survivors.
Board certified pediatric geneticists, pediatric oncologists and genetics counselors evaluate patients at the Children’s Hospital of Michigan to determine if there is a hereditary/genetic basis for developing cancer. This is available for patients with cancer that have a known strong hereditary pattern (e.g. retinoblastoma) or a family history to suggest a hereditary cancer predisposition syndrome.
According to the National Cancer Institute, as of 2014, more than 400,000 cancer survivors were first diagnosed when they were under the age of 20. In order to meet the needs of these patients, DMC Children’s Hospital of Michigan offers a Childhood Cancer Survivorship Program, for survivors of childhood cancer to receive the vital follow-up care they need for continued health into young adulthood.
The Children’s Hospital of Michigan is internationally recognized as an innovator in the care of pediatric and young adult patients with hemophilia, hemostasis thrombosis and other blood diseases. Clinical trials provide patients with the latest treatment modalities and in-depth surveillance of complications. The division operates a coagulation laboratory, which provides great flexibility in making a diagnosis, devising new coagulation tests, and conducting studies of new innovative therapies. The division also provides complete diagnostic testing, carrier detection and genetic counseling, hepatitis testing, radionucleotide (nonsurgical) isotope synovectomy and immune tolerance programs for inhibitors. Family education, support groups and education about home care options are also available for pediatric patients with bleeding disorders.
Hemophilia Comprehensive Clinic: This clinic visit is for patients that have been diagnosed with hemophilia.
Bleeding Disorder Comprehensive Clinic: This clinic is for patients that have been diagnosed with non-hemophilia, bleeding disorders. This includes von Willebrand disease, platelet dysfunction, and all other factor deficiencies.
Thrombosis Clinic: This clinic evaluates patients with thrombotic disorders and congenital and acquired thrombophilia. All patients are prescribed anticoagulation according to the current guidelines and are followed for evaluation of post-thrombotic complications.
Girl Squad Clinic: This clinic combines the efforts of two specialties: Hematology and Adolescent Medicine or Gynecology. The clinic is for patients who have been diagnosed with heavy or prolonged menstruation (periods) who are diagnosed with a bleeding disorder or is currently being investigated for a cause of heavy/prolonged menstrual bleeding.
The Comprehensive Sickle Cell Clinic serves one of the largest concentrated populations of patients with sickle cell disease in the country. We follow 700 pediatric patients, are involved to varying degrees in the care of 1300 additional adult patients, and are the leader in city wide-efforts between multiple health systems to better care for adults with the disease. We are currently a site for over 10 pharma initiated clinical trials and are regularly a preferred site due to our large patient population and experience in these trials. We are intimately associated with the Sickle Cell Disease Association of America, a patient advocacy group located in the city of Detroit that also runs the Michigan Newborn Screening Program and seamlessly facilitates referrals of all new cases in the state. We work very closely on a clinical and academic basis with a growing commercial lab nearby specializing in novel assays of red blood cell and vascular adhesion as well as overall RBC health, which have been targeted as important biomarkers by pharmaceutical companies in the space. These features of our center place us at the forefront of sickle cell disease research and provide excellent opportunities for novel research and academic advancement.
Our Team is Dedicated to You
Pediatric Hematology Oncology Attendings
Learn about our University Pediatricians Attendings
Advanced Practice Providers
Want to learn more about our distinguished specialists? Click the button below to be taken to our Faculty Directory.
Education
Fellowship Training Program
The fellowship program dating back to the 1950’s, has trained over 100 specialists who have become leaders in the field both nationally and internationally. Current fellowship alumni are practicing at institutions including: Children’s Hospital of Michigan, St. Jude Children’s Research Hospital, Children’s Hospital-Alabama, Phoenix Children’s Hospital, Mercy Children’s Hospital Kansas City, St. Louis Children’s Hospital, UT Southwestern Medical Center, Seattle Children’s Hospital, Children’s Healthcare of Atlanta, Michigan State University, Valley Children’s Hospital California, University of South Alabama, All India Institute
A component for American Board of Pediatrics certification in Pediatric Hematology/Oncology, fellows must conduct a research project. In the recent era, multiple fellows in the division have been recipients of the highly competitive Children’s Hospital of Michigan Wolf Zuelzer Fellowship Research Award.
2020: Katherine Regling, DO
2019: Margaret Shatara, MD
2018: Tristan Knight, MD
2017: Jonathan Schwartz, DO
2016: Ahmar Zaidi, MD
2014: Santosh Hanmod, MD MPH
2013: Mara Rubenstein, MD
2012: Ayesha Zia, MD
2011: Meret Henry, MD
2010: Abdul Hafeez Siddiqui, MD
2009: Ana Xavier, MD [Runner up; Recipient of the St Baldrick’s Foundation/Post-Doctoral Fellowship for Childhood Cancer]
2008: Michael Callaghan, MD
Research
Hematology and Oncology Research at Children’s Hospital of Michigan
The faculty are actively engaged in conducting multiple clinical and translational research projects in malignant hematology, immunohematology, thrombosis and coagulation disorders and hemoglobinopathies through an academic affiliation with Central Michigan University. The Division research is supported by 4 endowed research chairs [Ring Screw Textron Endowed Chair in Pediatric Cancer; Georgie Ginopolis Chair for Pediatric Cancer and Hematology; Purcell-Lusher Chair for Research in Pediatric Thrombosis Hemostasis; Barnhart-Lusher Hemostasis Research Endowed Chair].
1. Evaluation of coagulation in pediatric oncology patients using thromboelastography (TEG) before and after platelet transfusions. [Drs. Toll, Gorsi and Chitlur]
2. Randomized control study of glutamine for prevention of chemotherapy induced mucositis in pediatric patients with cancer. [Dr. Gorsi]
3. National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 [through UAB]. [Dr. Gorsi]
4. Patient-Centered Outcomes Research Institute (PCORI)-funded study conducted at 17 institutions including CHM utilizing a mixed models approach evaluating clinical outcomes, patient-reported quality of life and patient/family perceptions for children with AML managed as inpatient vs. outpatient. [Dr. Henry]
5. Derby for Kids [in collaboration with the University of Michigan] Integrative clinical sequencing of multi-ethnic, multi-institutional cohort of pediatric cancer patients to study tumor biology of minority children.
Acute myeloid leukemia (AML) accounts for one quarter of childhood leukemias though accounts for half of the deaths in this patient group. Although cure rates continue to improve, up to 30% of patients with high-risk disease still require stem cell transplants in first remission. This highlights the need to develop new chemotherapy-based treatments. [Dr. Taub in collaboration with Dr. Ge at the Karmanos Cancer Institute]
1. Developing novel combination therapies for children with FLT3-ITD AML: gilteritinib + CUDC-907
2. Identifying the basis for resistance to azacytidine/venetoclax combination therapy and develop new therapies to target the mechanism of resistance to prevent the development of therapy resistant AML.
3. Identifying the mechanisms linked to chromosome 21 and the extremely high cure rates of Down syndrome children with AML.
Two additional projects are being conducted by hematology/oncology fellows:
1. Eman Al-Antary, MD (2019-2022) Pediatric Hematology/Oncology Fellow. Children’s Hospital of Michigan. Novel Therapy for Cytarabine Resistant AML Utilizing the Combination of AZD5991 and ONC213. Funded by the Children’s Hospital of Michigan Foundation $30,000.
2. Avante Gupte, MD (2019-2022) Pediatric Hematology/Oncology Fellow. Children’s Hospital of Michigan. Co-targeting Bcl-2 and CDK9 to combat cytarabine resistance in AML. Funded by the Children’s Hospital of Michigan Foundation $11,000.
Kids Without Cancer Zebrafish Initiative [zebrafish aquatic housing system in the Integrative Biosciences Center (IBio) at Wayne State University] was funded by Kids Without Cancer through the Children’s Hospital of Michigan Foundation. [Dr. Taub in collaboration with Drs. Thummel and Baker at Wayne State University]
1. Using the zebrafish as an animal model to study environmental exposures including pesticides which may be linked to the development of childhood ALL.
2. Using the zebrafish model to study the progression of human retinoblastoma.
1. Cellular characteristics and interactions in patients with bone marrow failure.
2. Mechanisms of anti-tumor immunological response against Hodgkin lymphoma cells and the tumor microenvironment in Hodgkin lymphoma. [Dr. Henry]
3. Identification and characterization of acute myeloid leukemia stem cells.
4. Flow cytometric peripheral blood and bone marrow cellular characteristics in patients with hemophagocytic lymphohistiocytosis.
5. B cell and plasma cell study of patients with immune deficiency, immune dysregulation and autoimmune disorders.
6. Characterization of T-large granular lymphocyte populations in children and young adults.
The Sickle cell Pain: Intervention with Capsaicin Exposure SPICE pilot trial (NCT03899246) is studying the use of 8% topical capsaicin for neuropathic pain in pediatric sickle cell disease. [Drs. Glaros, Sarnaik]
The assessment of thromboinflammation and thromboinflammatory markers and their role in hemostasis in patients receiving ECMO therapy. [Drs. Regling, Chitlur, Rajpurkar]
A Randomized, Open-Label, Active Controlled, Safety and Extrapolated Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of a Venous Thromboembolic Event
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)
ATHN 15: Characterizing the Real-World Use of Direct Oral Anticoagulants (DOAC) in Pediatric Thrombosis Patients
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions
A Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy and Pharmacokinetics Of Intravenous Recombinant Coagulation Factor VIII Fc-Von Willebrand Factor-XTEN Fusion Protein (Rfviiifc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age with Severe Hemophilia A
Hemlibra® Pups and Nuwiq® ITI Study
EQUIPT: Evaluating Quality of life In Period Treatment
A Prospective, Multi-National, Non-Interventional Study in Haemophilia A and B Patients With or Without Inhibitors Treated According yo Routine Clinical Treatment Practice (Explorer™6)
Efficacy and Safety of Concizumab Prophylaxis in Patients with Haemophilia A or B Without Inhibitors
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab In Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors
Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children (the “Kids-DOTT” Trial)
Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Inherited Bleeding Disorders
Pediatric and Adult Intercontinental Registry on Chronic ITP
Pediatric Pulmonary Embolism- A Survey Of Diagnostic And Management Practices
An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A
The Molecular and Clinical Biology of Von Willebrand Disease
The majority of our research projects/programs and our ability to participate in national clinical trials has been supported by the Children’s Hospital of Michigan Foundation (including the endowed chairs) and organizations including National Institutes of Health, Hyundai Hope on Wheels, St. Baldrick’s Foundation, Kids Without Cancer, U Can-cer Vive Foundation, Litvak Foundation, and the Hemophilia of Georgia Clinical Scientist Development Award program.
Recent Research Publications
Brian Berman, MD
Saleem, S., Berman, B., Deep vein thrombosis and pulmonary embolism in the setting of mycoplasma infection. Case Reports in Medicine, 2020; 8708417. DOI0.1155/2020/8708417)
Meera B. Chitlur, MD
Tran DQ, Benson CC, Boice JA, Chitlur M, Dunn AL, Escobar MA, Gupta K, Johnsen JM, Jorgenson J, Martin SD, Martin S, Meeks SL, Narvaez AA Jr, Quon DV, Reding MT, Reiss UM, Savage B, Schafer K, Steiner B, Thornburg C, Volland LM, von Drygalski A. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia. Expert Rev Hematol. 2023 Mar;16(sup1):19-37.
Bartlett R, Arachichilage DJ, Chitlur M, Hui SR, Neunert C, Doyle A, Retter A, Hunt BJ, Lim HS, Saini A, Renné T, Kostousov V, Teruya J. The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation. Semin Thromb Hemost. 2023 Feb 7.
[Editorial] Chitlur M. Desmopressin revisited in mild hemophilia A. Blood. 2022 Sep 8;140(10):1063-1064. doi: 10.1182/blood.2022017652. PMID: 36074536.
Michael Callaghan, MD
Hulbert, M, Manwani, D, Meier, ER, Callaghan, M, et al. Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center. Pediatr Blood Cancer. 2023; 70:e29961. https://doi.org/10.1002/pbc.29961
Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, Hardesty B, Shima M, Pollock T, Slev P, Oldenburg J, Ozelo MC, Stieltjes N, Castet SM, Mahlangu J, Peyvandi F, Kazmi R, Schved JF, Leavitt AD, Callaghan M, Pan-Petesch B, Quon DV, Andrews J, Trinh A, Li M, Wong WY. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum Gene Ther. 2022 Apr;33(7-8):432-441. doi: 10.1089/hum.2021.287. Epub 2022 Mar 16. PMID: 35156839; PMCID: PMC9063149.
Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from HAVEN 1-4 studies. Callaghan MU., Negrier, C, Paz-Priel, I, Chang, T et al. Blood. 2021 [Accepted]
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Zaidi, AU, Minniti, CM*, Crouch, A, Nouraie, SM, Crouch, G, Callaghan, MU, Glassberg, J, Simon, J,Gordeuk, V, Han J, Klings, SE. Blood Advances [Accepted]
Reversible Cerebral Vasoconstriction Syndrome and Sickle Cell Disease: A Case Report. Regling K, Pomerantz D, Narayanan S, Altinok D, Sivaswamy L, Marupudi NI, Callaghan MU, Martin A. J Pediatr Hematol Oncol. 2021 Jan;43(1):e95-e98. doi: 10.1097/MPH.0000000000001683.PMID: 31789782
Discussing investigational AAV gene therapy with hemophilia patients: A guide. Sidonio RF Jr, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE.Blood Rev. 2020 Nov 9:100759. doi: 10.1016/j.blre.2020.100759. Online ahead of print. PMID: 33183859 Review.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, Negrier C, Callaghan MU, Levy GG. Thromb Haemost. 2020 Oct 21. doi: 10.1055/s-0040-1717114. Online ahead of print. PMID: 33086400
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers. Pittman D, Hines PC, Beidler DR, Rybin D, Frelinger AL, Michelson AD, Liu K, Gao X, White J, Zaidi AU, Charnigo RJ, Callaghan MU. Blood. 2020 Oct 16:blood.2020006020. doi: 10.1182/blood.2020006020. Online ahead of print.PMID: 33067606
Bortezomib treatment of steroid-refractory Evans syndrome in children. Beydoun SB, Persaud Y, Lafferty J, Callaghan MU, Savaşan S. Pediatr Blood Cancer. 2020 Dec;67(12):e28725. doi: 10.1002/pbc.28725. Epub 2020 Sep 23. PMID: 32969165
ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. Fisher MH, Kirkpatrick GD, Stevens B, Jones C, Callaghan M, Rajpurkar M, Fulbright J, Cooper MA, Rowley J, Porter CC, Gutierrez-Hartmann A, Jones K, Jordan C, Pietras EM, Di Paola J. JCI Insight. 2020 Sep 17;5(18):e140332. doi: 10.1172/jci.insight.140332.PMID: 32841218
Urinary Tract Infection in Febrile Children with Sickle Cell Disease Who Present to the Emergency Room with Fever. Patel N, Farooqi A, Callaghan M, Sethuraman U. J Clin Med. 2020 May 19;9(5):1531. doi: 10.3390/jcm9051531. PMID: 32438767
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. Malec LM, Croteau SE, Callaghan MU, Sidonio RF Jr. Haemophilia. 2020 May;26(3):e128-e129. doi: 10.1111/hae.13943. Epub 2020 Mar 6.PMID: 32142196
Successful Treatment of an Adolescent Male With Severe Refractory Evans Syndrome Using Bortezomib-based Therapy. Knight T, Ravindranath Y, Callaghan MU. J Pediatr Hematol Oncol. 2020 Mar;42(2):e110-e113. doi: 10.1097/MPH.0000000000001325. PMID: 30299351
Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report. Regling K, Callaghan MU, Rajpurkar M. Pediatr Blood Cancer. 2020 Feb;67(2):e28094. doi: 10.1002/pbc.28094. Epub 2019 Nov 20. PMID: 31749252
Thalassemia . In: Benign Hematologic Disorders in Children. Shamoun MU, Callaghan MU. 1st ed. Kamat D, editor. Switzerland: Springer; 2021. Chapter 6; p.91-98.
Hemophilia . In: Benign Hematologic Disorders in Children. Callaghan MU. 1st ed. Kamat DM, editor. Switzerland: Springer; 2021. Chapter 17; p.247-258.
Hamza Gorsi, MD
A novel finding in pediatric leiomyosarcoma: Expanding spectrum of FGFR rearrangements in childhood cancers. Persaud Y, Bagla S, Shanti CM, Shehata BM, Ravindranath Y, Gorsi HS.Pediatr Blood Cancer. 2020 Nov 16:e28805. doi: 10.1002/pbc.28805. Online ahead of print.PMID: 33200450 No abstract available.
Pneumocephalus in a Pediatric Patient with Glioma Receiving Trametinib. Gorsi H, Marupudi NI, Sood S, Altinok D, Yankelevich M.Pediatr Neurosurg. 2020;55(1):51-53. doi: 10.1159/000503639. Epub 2019 Oct 29.PMID: 31661699
Yankelevich M; Finlay J; Gorsi H; Mody R. Molecular Insights into Malignant Progression of Atypical Choroid Plexus Papilloma. (in print at Molecular case studies)
Meret Henry, MD
Savaşan S, AlQanber B, Henry M, Buck S, Gadgeel M. Differing reflections of paediatric classical Hodgkin’s lymphoma on local and distant immunological microenvironments: a flow cytometric study. J Clin Pathol. 2020 Mar;73(3):176-179. doi: 10.1136/jclinpath-2019-205967.
Bulent Ozgonenel, MD
Ozgonenel B, Nash TA, Rajpurkar M. Blood Components for Pediatric Transfusions. Pediatr Rev. 2020 May;41(5):259-261.
Chitlur M., Ozgonenel B., Kulkarni R. Hemophilia and Related Conditions. In: Kellerman R, Rakel D, Eds) Conn’s Current Therapy 2020, 72nd Edition, Philadelphia, 2019. pp. 417-423
Ozgonenel B. Transfusion Medicine for Pediatrics In: (Kamat and Frei-Jones, Eds) Benign Hematologic Disorders in Children: A Clinical Guide 2020
Madhvi Rajpurkar, MD
Rajpurkar M, Forsyth A, Manco-Johnson M. Current Challenges in men and women with mild- moderate Hemophilia. Haemophilia (accepted September 2020)
DeSancho M, Munn, JE, Billett, HH, Cheng D, Holmes, C, Jaffray, J, Malone, M, Patel, K, Sharathkumar, A, Thornburg, CD, Wang, M, Watson, C, Rajpurkar, M on behalf of the Study Investigators. Transition of Care for Pediatric and Adult Patients with Venous Thromboembolism: A National Quality Improvement Project from the American Thrombosis and Hemostasis Network (ATHN). Thrombosis Research (accepted December 2020)
Fisher MH, Kirkpatrick GD, Stevens BM, Jones CL, Callaghan MU, Rajpurkar M, Fulbright J, Cooper MA, Rowley J, Porter CC, Gutierrez-Hartmann A, Jones K, Jordan CT, Pietras EM, Di Paola J. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight. 2020 Aug 25:140332; PMID: 32841218
Katherine Regling, DO
Regling K and Chitlur M. Disorders of Platelet Function. D.M. Kamat and M.J. Frei-Jones (Ed.), Benign Hematologic Disorders in Children: A Clinical Guide. SpringerNature 2021.
Bagla S, Regling K, Wakeling E, Gadgeel M, Buck S, Zaidi A, Flore L, Chicka M, Schiffer C, Chitlur M, Ravindranath Y. Distinctive phenotypes in two children with novel germline RUNX1 mutations – one with myeloid malignancy and increased fetal hemoglobin. Pediatr Hematol Oncol. 2020.
Sureyya Savasan, MD
Al-Antary E*, Henry M, Spruit J, Yankelevich M, Chu R, Ravindranath Y, Savaşan S. Patterns and correlates of preserved humoral immunity to vaccines in children following allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2020 Dec 16:e13936. doi: 10.1111/petr.13936. Epub ahead of print. PMID: 33326673.
Savaşan S, George A, Sokolowski C, McGraw BJ, Rademacher H. Aerodigestive adverse effects during intravenous pentamidine infusion for Pneumocystis jirovecii pneumonia prophylaxis. Pediatr Blood Cancer. 2021 Jan;68(1):e28714. doi: 10.1002/pbc.28714. Epub 2020 Sep 26. PMID: 32979296.
Beydoun SB*, Persaud Y, Lafferty J, Callaghan MU, Savaşan S. Bortezomib treatment of steroid-refractory Evans syndrome in children. Pediatr Blood Cancer. 2020 Dec;67(12):e28725. doi: 10.1002/pbc.28725. Epub 2020 Sep 23. PMID: 32969165.
Gadgeel M, Gabali A, Savaşan S. Characteristic flow cytometric profile of ectopic intra-thyroidal thymic tissue in children. Cytometry B Clin Cytom. 2020 Sep 21. doi: 10.1002/cyto.b.21954. Epub ahead of print. PMID: 32956519.
Suryaprakash S*, George A, Langenburg S, Savaşan S. Pediatric recurrent Rosai-Dorfman disease with germline heterozygous SLC29A3 and somatic MAP2K1 mutations. Ann Hematol. 2020 Dec;99(12):2965-2967. doi: 10.1007/s00277-020-04264-3. Epub 2020 Sep 17. PMID: 32944792.
Savaşan S, Buck S, Gadgeel M, Poulik J. Persistent pseudo-Pelger-Huët anomaly. Ann Hematol. 2020 Aug 29. doi: 10.1007/s00277-020-04242-9. Epub ahead of print. PMID: 32862285.
Singh P*, Secord E, Pappas K, Savaşan S. An infant with severe combined immunodeficiency, osteopetrosis, chromosomally integrated herpesvirus-6 infection, and hemophagocytic syndrome: What are the links? Pediatr Blood Cancer. 2021 Jan;68(1):e28564. doi: 10.1002/pbc.28564. Epub 2020 Aug 18. PMID: 32808422.
Suryaprakash S*, El-Baba M, Walkovich KJ, Savaşan S. Expanding clinical spectrum of female X-linked lymphoproliferative syndrome 2. Pediatr Blood Cancer. 2020 Jul 19:e28592.
Seddiq M*, Gadgeel M, Persaud Y, Lafferty J, Savaşan S. Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim. Br J Haematol. 2020 Jun 8.
Savaşan S, Al-Qanber B, Buck S, Wakeling E, Gadgeel M. Clonal T-cell large granular lymphocyte proliferations in childhood and young adult immune dysregulation conditions. Pediatr Blood Cancer. 2020 May;67(5):e28231.
Schultz KR, Kariminia A, Ng B, Abdossamadi S, Lauener M, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savasan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, Azadpour S, Ostroumov E, Subrt P, Halevy A, Mostafavi S, Cuvelier GDE. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies. Blood. 2020 Apr 9;135(15):1287-1298.
Spruit JL, Knight T*, Sweeney C, Salimnia H, Savaşan S. Clostridium difficile infection in a children’s hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations. Pediatr Hematol Oncol. 2020 Apr;37(3):211-222.
Savaşan S, AlQanber B, Henry M, Buck S, Gadgeel M. Differing reflections of paediatric classical Hodgkin’s lymphoma on local and distant immunological microenvironments: a flow cytometric study. J Clin Pathol. 2020 Mar;73(3):176-179.
Gadgeel M, Al-Qanber B, Buck S, Savaşan S. CD20+ T Cells in Primary Mediastinal Large B Cell Lymphoma Microenvironment. Cytometry B Clin Cytom. 2020 Jan;98(1):16-18.
Mark Shamoun, MD
CD14/16 monocyte profiling in juvenile myelomonocytic leukemia. Gadgeel M, Bagla S, Buck S, Shamoun M, Ravindranath Y.Pediatr Blood Cancer. 2020 Sep;67(9):e28555. doi: 10.1002/pbc.28555. Epub 2020 Jul 10.
Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis. Persaud Y, Shamoun M, Chitlur M, Des Rosier KJ, Taub JW.
Jeffrey Taub, MD
Taub, Jeffrey W., Buck, Steven A., Xavier, Ana C., Edwards, Holly, Matherly, Larry H., Ge, Yubin. The evolution and history of Vinca alkaloids: From The Big Bang to the treatment of pediatric acute leukemia. 2024 Aug 9, doi/10.1002/pbc.31247
Taub, Ge Y, Xavier AC. COVID-19 and Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer May 13:e28400, 2020
Luedtke DA, Su Y, Ma J, Li X, Buck SA, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Lin H, Taub JW, Ge Y. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduction and Targeted Therapy. 2020 Feb 26;5:17. doi: 10.1038/s41392-020-0112-3. eCollection 2020.
Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, Yang J, Miller R, Wang G, Zhao L, Wang Y, Lin H, Taub JW, Ge Y. The HDAC and PI3K Dual Inhibitor CUDC-907 Synergistically Enhances the Antileukemic Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia. Haematologica (2020 Mar 12:haematol.2019.233445.
Yankelevich M, Hoogstra D, Abrams J, Chu R, Bhambhami K, Taub, JW. Delayed granulocyte colony-stimulating factor (G-CSF) administration after chemotherapy reduces total G-CSF doses without affecting neutrophil recovery in a randomized clinical study in children with solid tumors. Pediatric Hematology-Oncology 9:1-11, 2020.
Karol SE, Cooper TM, Mead PE, Crews KR, Panetta JC, Alexander TB, Taub JW, Lacayo NJ, Heym KM, Kuo DJ, Schiff DE, Bhojwani D, Ge Y, Klco JM, Ribeiro RC, Inaba H, Pui CH, Rubnitz JE. Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer 2020 Aug 18. doi: 10.1002/cncr.3315
Liu F, Kalpage HA, Wang D, Edwards H, Hüttemann M, Ma J, Su U, Carter J, Li X, Polin L, Kushner J, Dzinic SH, White K, Wang G, Taub JW, Ge Y. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers 12(9):E2400, 2020.
Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Hüttemann M, Taub JW, Ge Y. Targeting Multiple Signaling Pathways: The New Approach to Acute Myeloid Leukemia Therapy. Signal Transduction and Targeted Therapy 2020 Dec 18;5(1):288
Stewart R, Brahimi X, Iadipaolo AS, Peters C, Harper FWK, Taub JW, Rabinak CA, Marusak H. Childhood cancer-related posttraumatic stress and resilience have distinct effects on volume of the amygdala and hippocampus. Adversity and Resilience Science 2020 in press
Carter J, Hege K, Edwards E, Huttemann M, Taub JW, Ge Y. Targeting Mitochondrial Respiration for the Treatment of Acute Myeloid Leukemia. Biochemical Pharmacology 2020 Dec;182:114253
Ahmar Zaidi, MD
Zaidi, AU*, Minniti, CM*, Crouch, A, Nouraie, SM, Crouch, G, Callaghan, MU, Glassberg, J, Simon, J,Gordeuk, V, Han J, Klings, SE. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Advances. https://doi.org/10.1182/bloodadvances.2020003456
Zaidi, AU, Glaros AK, Weyand AC. Navigating a new terrain: how Twitter is changing hematologists. Blood Advances [in press]
Pittman D, Hines PC, Beidler DR, Rybin D, Frelinger AL, Michelson AD, Liu K, Gao X, White J, Zaidi AU, Charnigo RJ, Callaghan MU. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers. Blood. 2020 Oct 16. PMID: 33067606
Weyand AC, Zaidi AU. Tweetopoiesis: A peripheral review of Twitter for hematologists. Am J Hematol. 2020 Oct 16. PMID: 33064309.
Bagla S, Regling KA, Wakeling EN, Gadgeel M, Buck S, Zaidi AU, Flore LA, Chicka M, Schiffer CA, Chitlur MB, Ravindranath Y. Distinctive phenotypes in two children with novel germline RUNX1 mutations – one with myeloid malignancy and increased fetal hemoglobin. Pediatr Hematol Oncol. 2020 Sep 29:1-15. doi: 10.1080/08880018.2020.1814463. PMID: 32990483
Zaidi AU, Buck S, Gadgeel M, Herrera-Martinez M, Mohan A, Johnson K, Bagla S, Johnson RM, Ravindranath Y. Clinical Diagnosis of Red Cell Membrane Disorders: Comparison of Osmotic Gradient Ektacytometry and Eosin Maleimide (EMA) Fluorescence Test for Red Cell Band 3 (AE1, SLC4A1) Content for Clinical Diagnosis. Front Physiol. 2020 Jun 19;11:636. doi: 10.3389/fphys.2020.00636. PMID: 32636758
Michael Callaghan, MD
Callaghan, MU. Hemophilia Updates. Symposium American Society of Hematology December 2020
Callaghan, MU. ATHN 16: Sevenfact for the treatment of Bleeding with Inhibitors, ATHN Data Summit October 2020
Glaros, AK, Callaghan, MU, Zaidi, AU. Sickle cell Pain: Intervention with Capsaicin Exposure (SPICE). Presented at Foundation for Sickle Cell Research Annual Meeting, Jun 2020. [Oral Abstract]
White, J, Liu, K, Gao, X, Thornton, T, Zaidi, AU, Callaghan, MU, and Hines, P. Establishment of Steady State Adhesion Indices in Sickle Cell disease: Clinical Application of a Standardized Adhesion Bioassay, Presented at Foundation for Sickle Cell Research Annual Meeting, April 28-30, 2017, Ft. Lauderdale, FL [Oral Abstract]
M Callaghan, B Trzaskoma, R Ko, L Lee, A Patel, E Tzeng, M Shah Factor VIII use in the treatment of breakthrough bleeds in persons with haemophilia a without inhibitors on emicizumab prophylaxis: the phase III HAVEN 3 study experience. BRITISH JOURNAL OF HAEMATOLOGY 189, 44-45. British Hematology Society, Glasgow Scottland 2020 [Oral Abstract]
Callaghan MU, Kruse-Jares, R, Malanghu, J Understanding Emicizumab, European Association for Hemophilia and Allied Disorders, The Hague, The Netherlands February 2020
MU Callaghan, CG Negrier, I Paz-Priel, TYC Chang, S Chebon, M Lehle, .Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies Blood 2020 Presented Virtually at American Society of Hematology Annual Meeting
Pipe, SW, Callaghan, MU et al. In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors Blood 2020 Presented Virtually at American Society of Hematology Annual Meeting
Zaidi, AU, Shah, N, Thomas, RT, Hannan, B, Shareef, MO, Zaidi, AU, Callaghan, MU. SickleFit: Adherence, Feasibility and Validation of Fitbit Metrics In Sickle Cell Disease Patients. Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020. [cancelled due to COVID19]
Zaidi, AU, *Glaros, AK, Callaghan, MU. A 30-Day Twitter Profile of #sicklecell During Two New Drug Approvals and a Major Conference. Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020. [cancelled due to COVID19]
L Bou-Maroun, *P Singh, A Zaidi, M Callaghan. Double Chelation Therapy In Pediatric Transfusion Associated Iron Overload. Pediatric Blood & Cancer 67, S17-S18 Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020. [cancelled due to COVID19]
R Razvi, R Thomas, S Wang, S Meinke, M Callaghan, A Zaidi. STUDYING THE INCIDENCE OF CANNABIS USE IN TEENAGERS WITH SICKLE CELL DISEASE, AN INTERIM ANALYSIS. PEDIATRIC BLOOD & CANCER 67, S32-S33 Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020. [cancelled due to COVID19]
Hamza Gorsi, MD
Gorsi H, Yankelevich M; Ongoing response in a multiply relapsed metastatic posterior fossa ependymoma A after vorinostat and concomitant irradiation (Accepted for ISPNO 2020)
Toll S, Gorsi H: Central nervous system germinoma in two Caucasian American siblings with autism spectrum disorder (Accepted for ISPNO 2020)
Patil, P; Gorsi, H. CNS sarcoma in a toddler with novel balanced translocation of t(8;11)(q13;q13). (Presented at SNO 2020).
Gupte, A, Toll, S; Marupudi N, Gorsi, H. Report of NTRK Fusion in a Pediatric Patient with Spinal Gangliocytoma ( Presented at SNO 2020)
Yogindra P. Persaud, M.D., Hamza S. Gorsi, M.D. MPH. FGFR Fusion in Head and Neck Leiomyosarcoma in Pediatrics – A Case Report. (Accepted for ASPHO 2020)
Meret Henry, MD
Leukemia, Lymphoma and Stem Cell Transplant Paper Presentations, Moderator, American Society of Pediatric Hematology/Oncology, July 2020, Virtual due to COVID-19
Sri Lakshmi Jamalapur, MD
Sri Lakshmi Jamalapur, Alexander K. Glaros, Yaddanapudi Ravindranath, Voxelotor (GBT440) in pediatric sickle cell disease: A review. Pediatric Hematology Oncology Journal, Volume 9, Issue 4, 2024, Pages 244-249, ISSN 2468-1245, https://doi.org/10.1016/j.phoj.2024.07.006.
Madhvi Rajpurkar, MD
Supportive Care to Minimize Early Death During Induction for Pediatric Patients With Acute Promyelocytic Leukemia (APL); A Report From the Children’s Oncology Group Trial AAML1331 PEDIATRIC BLOOD & CANCER VOLUME 67 PAGE S11-S11 PUBLISHED 2020 Kutny, M.; Alonzo, T.; Gerbing; Rajpurkar M
Katherine Regling, DO
Regling K, Cashen K, Gadgeel M, Xi Y, Herppich A, Tarasev M, Hines P, Chitlur M.B. Evaluation of Coagulation and Inflammatory Markers in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO). Blood (2020) 136 (Suppl 1): 14.
Sureyya Savasan, MD
Cuvelier GDE, Kariminia A, Nemecek ER, Kitko CL, Wahlstrom JT, Harris AC, Bittencourt H, Lewis VA, Pulsipher MA, Schechter T, Choi SW, Caywood EH, Bhatia M, Kasow KA, Jacobsohn DA, Oshrine B, Chaudhury S, Chewning JH, Flower A, Coulter D, Joyce M, Savasan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva A, Lawitschka A, Ng B, and Schultz KR. Naïve Helper T Cell and Regulatory T and NK Cell Subsets are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study. Presented at the 62th Annual ASH Meeting, 2020.
Gadgeel M, AlQanber B, Buck S, Taub JW, Ravindranath Y, Savaşan S. Aberrant mature myeloid cell CD56 expression in Down syndrome is not linked to leukomogenesis (Poster# 728). Presented at the Annual ASPHO Meeting in 2020.
Mark Shamoun, MD
Oral (Virtual) presentation at International Society of Thrombosis and Hemostasis: Coagulopathy in Pediatric Patients with Hemophagocytic Lymphohistiocytosis
Jeffrey Taub, MD
Gadgeel M, AlQanber B, Buck S, Taub JW, Yaddanapudi Ravindranath Y,Savaşan S. Aberrant mature myeloid cell CD56 expression in down syndrome is not linked to leukomogenesis. Annual meeting of the American Society of Pediatric Hematology Oncology, May 2020.
Ahmar Zaidi, MD
ASH Talk: Racial Health Disparaties and Sickle Cell Disease. American Society of Hematology 62nd Annual Meeting 2020. – Razvi, R, Meinke, S, Wang, S, Hannan, B, Thomas, R and Zaidi, AU. Studying the Incidence Of Cannabis Use in Teenagers With Sickle Cell Disease, an Interim Analysis. Presented at Foundation for Sickle Cell Research Annual Meeting, Sep 2020.
Glaros, AK, Callaghan, MU, Zaidi, AU. Sickle cell Pain: Intervention with Capsaicin Exposure (SPICE). Presented at Foundation for Sickle Cell Research Annual Meeting, Sep 2020 Posters
Zaidi, AU, Lipato, T, Alvarez, OA, Lonshteyn, A, Weycker A, Pham, N, Delea, TE, Agodoa, I, Cong, Z and Shah, N. Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US. Presented at the American Society of Hematology Annual Meeting, December 5-8, 2020, Virtual
Glaros, AK, Callaghan, MU, Zaidi, AU. Sickle Cell Pain: Intervention with Capsaicin Exposure (SPICE). Presented at the American Society of Hematology Annual Meeting, December 5-8, 2020, Virtual
Shah, N, Zaidi, AU, Callaghan, MU, Liles, D, Johnson, CE and De Castro, LM. Real World Evidence of Prescription Patterns and Effect of Oxbryta (voxelotor) for Patients with Sickle Cell Disease. Presented at the American Society of Hematology Annual Meeting, December 5-8, 2020, Virtual
Zaidi, AU, Shah, N, Thomas, RT, Hannan, B, Shareef, MO, Zaidi, AU, Callaghan, MU. SickleFit: Adherence, Feasibility and Validation of Fitbit Metrics In Sickle Cell Disease Patients. Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020.
Zaidi, AU, Glaros, AK, Callaghan, MU. A 30-Day Twitter Profile of #sicklecell During Two New Drug Approvals and a Major Conference. Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020.
Razvi, R, Meinke, S, Wang, S, Hannan, B, Thomas, R and Zaidi, AU. Studying the Incidence Of Cannabis Use in Teenagers With Sickle Cell Disease, an Interim Analysis. Accepted for presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting May 2020.
Michael Callaghan, MD
L-glutamine and red blood cell membrane health – Emmaus Life Sciences Investigator Initiated Grant, $274,000 (Callaghan Co-I, Zaidi PI)
Hemophilia Biomarkers and Proteomics, Hemostasis Thrombosis Research Society, $150,0000 (Callaghan Mentor, PI Regling)
Effect of hydroxyurea on TCD velocity in sickle cell disease, Central Michigan School of Medicine $3,000 (Callaghan Mentor, PI Peine)
Effect of hydroxyurea on TCD velocity in sickle cell disease, Blue Cross Blue Shield Foundation $ 6,000 (Callaghan Mentor, PI Peine)
Clinical Trials
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE Kids 2) – Open to accrual – (Site PI)
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ? 1 IU/dL Receiving Prophylactic FVIII, Sponsor Biomarin One subject on study $60,340– (Site PI)
A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Individuals with Severe Hemophilia A, Sponsor Biomarin One subject on study $40,200– (Site PI)
Global Prospective Laboratory Study for Adenovirus-Associated Virus (AAV) Seroprevalence in HemophiliaA Patients with Residual Factor VIII Levels <2IU/dL Who Were Previously Treated with Factor VIII Concentrates Sponsor Biomarin 17 subject enrolled on study $26,368—(Site PI)
Katherine Regling, DO
HTRS/Novo-Nordisk Clinical Fellowship Award in Hemophilia and Rare Bleeding Disorders
Sureyya Savasan, MD
Clonal T-Large Granular Lymphocyte Proliferations in Pediatric Immune Dysregulation Conditions funded by Children’s Foundation, PI (7/1/2019 – 9/30 2020); $95, 070
Extension of the previous grant: Clonal T-Large Granular Lymphocyte Proliferations in Pediatric Immune Dysregulation Conditions funded by Children’s Foundation, PI (7/1/2019 – 6/30 2021); Totaling $163.205
Ahmar Zaidi, MD
Emmaus Life Sciences Investigator Initiated Grant” L-glutamine and red blood cell membrane health, $274,000- 15% salary support
Novartis Investigator Initiated Grant “Biomarkers of rheology, coagulation, and proteomics in patients receiving crizanlizumab”. $500,000 – 35% salary support
CDC Sickle Cell Surveillance Grant, Subject Matter Expert (for all sites) and Site-PI, $10,000
Brian Berman, MD
Awards:
Community House of Birmingham Michigan Pillar Society Inductee 2020 (Wellness & Education)
Michael Callaghan, MD
Awards:
Hour Top Doctors 2020
Top Doctors in America 2020
Other Professional Accomplishments:
Editorial Board, Journal of Clinical Medicine (Impact Factor, 2019 = 3.3)
Creator co-host Cheat Codes: A Sickle Cell Podcast (sponsored by Novartis and Global blood Therapeutics) – 25 Episodes
Hamza Gorsi, MD
Awards:
Grants Ashok and Ingrid Sarnaik Junior faculty grant for the project title “Evaluation of coagulation in pediatric oncology patients using thromboelastography before and after transfusions”.
Madhvi Rajpurkar, MD
Other Professional Accomplishments:
Chair, Pediatric pulmonary embolism working group at the International Society on Hemostasis Thrombosis
Katherine Regling, DO
Awards:
Wayne State University Faculty Teaching Award 2019-20
Wolf Zuelzer Fellow Research Award
Mark Shamoun, MD
Other Professional Accomplishments:
Book chapter on Beta Thalassemia for Benign Hematologic Disorders in Children: A Clinical Guide
Jeffrey Taub, MD
Awards:
American College of Medical Genetics, Education Committee, Member
Other Professional Accomplishments:
Taub JW. Leukemia in Children with Down Syndrome: Treading Carefully with Clinical Trials. National Institutes of Health: Clinical Trials in Down Syndrome for Co-occurring Conditions Across the Lifespan Workshop. May 7, 2020.
Taub JW. Clues to Diagnosing Pediatric Cancers: Pearls and Pitfalls. Chat with a Pediatric Specialist. Children’s Hospital of Michigan. May 15, 2020.
Taub JW. Translational Research-How Your Patients Can Inspire Research Projects. Children’s Hospital of Michigan Fellow Research Lecture. August 12, 2020
Ahmar Zaidi, MD
Other Professional Accomplishments:
Sickle cell disease: how research in one disease can drive us all forward. TEDxDetroit 2020
Editor in Chief, American Society of Hematology News Daily 2020
Associate Editor, Digital Features, Blood Advances (Impact Factor, 2019 = 5)
Creator co-host Cheat Codes: A Sickle Cell Podcast (sponsored by Novartis and Global Blood Therapeutics)
Board Member, Medical and Research Advisory Committee, Sickle Cell Disease Association of America
Board Chair, Sickle Cell Health Reproductive Education Directive
Member, Blood Components Committee Detroit Medical Center
Member, Clinical Competency Committee Children’s Hospital of Michigan
Advocacy & Other Special Areas of Focus
Celebration of Life
For more than two decades, childhood cancer survivors at the Children’s Hospital of Michigan along with their friends and families gather yearly for the Children’s Hospital of Michigan Celebration of Life Program. This incredible, heartwarming event is organized by the Children’s Hospital of Michigan Hematology Oncology Department to celebrate childhood cancer survivors treated at Children’s Hospital of Michigan.